Public Policy Resources

Share

As a recognized expert in cancer health policy, ACS CAN develops reports, white papers, testimony, fact sheets, regulatory comment letters and public policy on a wide range of issues related to preventing cancer and improving the health care system for persons with cancer and survivors.  We encourage you to use this resource to learn more about our issue priorities and policy work. If you can't find something you need, you may contact us by using our contact form and selecting Policy Resources from the drop-down menu.

Search for Resources

FILTER BY:

Woman seeing her physician

Access to Health Care

ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.

The American Cancer Society Cancer Action Network (ACS CAN) appreciates the opportunity to comment on the Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters (NBPP) for plan year 2026.

This factsheet seeks to debunk some of the misinformation that has been made about the enhanced ACA tax credits.

This factsheet provides background information on why Congress must acti swiftly to extend the enhanced ACA tax credits. 

Photo of ACS CAN Volunteers at Advocacy Event to Support Cancer Research Funding

Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

A coalition of 74 patient and provider groups has offered their support of H.R. 8412, the Clinical Trial Modernization Act, which would remove tax liabilities for financial support received while on clinical trials as well as create a safe harbor for sponsors offering such support.  

ACS CAN submitted comments on draft U.S. Food and Drug Administration (FDA) guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.

The House Energy and Commerce Committee sought community feedback on potential structural and policy changes at the National Institutes of Health.  ACS CAN offered suggestions related to NCI and the proposal's impacts on cancer research. 

Photo of Making Strides Against Breast Cancer Event Participant

Prevention and Early Detection

ACS CAN advocates for public policies that can prevent nearly half of all cancer deaths by ensuring access to recommended cancer screenings, protecting the public from skin cancer risk, reducing tobacco use and exposure to secondhand smoke and supporting people in increasing physical activity, eating a healthy diet, and managing their weight.

In 1999, the U.S. Department of Justice (DOJ) filed a lawsuit against major tobacco manufacturers Philip Morris USA, R.J. Reynolds Tobacco, Lorillard, and Altria to hold the industry accountable for more than 50 years of conspiring to defraud the public in violation of the Racketeer Influenced and Corrupt Organizations (RICO) Act. Big Tobacco, an industry which has for decades knowingly addicted and endangered the lives of millions of Americans for their own profit, must now post the truth about their deadly products, including at the point-of-sale (POS) for approximately 220,000 tobacco retailers.

The tobacco industry has a history of using litigation to avoid and delay laws and regulations enacted to safeguard the public. ACS CAN, with our tobacco control partners, has also relied on the courts to hold Big Tobacco accountable and to ensure the federal government is effectively implementing the Tobacco Control Act.

Implementation of graphic warnings in the U.S. has been thwarted by tobacco industry legal challenges. The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN), along with our partners, have fought back in the judicial system, using litigation to both compel the U.S. Food and Drug Administration (FDA) to issue graphic warning regulations and help the U.S. Department of Justice (DOJ) defend the regulations finalized by FDA.

Doctor and Patient

Health Equity

ACS CAN supports health equity efforts for all Americans so they may receive access to quality care, no matter their race, ethnicity, sexual orientation, income level or ZIP code. 

The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) along with partners appreciate the opportunity to comment on the Patient Navigation provisions of CY2025 Medicare Physician Fee Schedule.

The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) are united in the goal of achieving health equity and access to quality care across the cancer continuum through effective patient navigation. Yet to date, patient navigation services are still absen

A critical factor for eliminating disparities and ensuring health equity is the guarantee that all people have access to quality, affordable health care.